Genetic landscape of Parkinson’s disease in the Personalized Parkinson Project cohort
Preprint
Abstract
Background: Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder shaped by, amongst others, high-impact variants and common polygenic factors. The Personalized Parkinson Project (PPP) offers deep phenotyping and longitudinal follow-up of Dutch people with PD. Here, we characterize the genetic landscape and its interaction with lifestyle factors within PPP. Methods: We utilized three complementary approaches in N=507 persons with PD: 1) short-read PD gene panel sequencing of eight PD genes, 2) genome-wide genotyping array, and 3) targeted long-read sequencing of the GBA1 gene. Additionally, we calculated the mitochondrial-function polygenic score (MGS). Associations between genetic factors, smoking status, and age at onset (AAO) were assessed using non-parametric tests, correlation analyses, and multiple regression models. Results: Genetic screening of the participants revealed N=79 GBA1 (∼15%), N=3 LRRK2 , N=1 CHCHD2 , N=1 SNCA variant carrier, and N=9 heterozygous PRKN/PINK1 variants. We also observed an interaction between MGS and smoking: MGS was associated with earlier AAO in non-smokers in persons with iPD (N=414, β=-1.87, p=0.038). Conclusion: Our findings corroborate previously reported frequencies of variants in PD-associated genes in European populations, and suggest a potential association between smoking and a mitochondrial dysfunction signature in PD. Thus, even in persons without rare variants (iPD subgroup), complex genetic contributions remained relevant. Our study supports future downstream stratification and personalized medicine approaches with high-impact variants and polygenic risk scores.Keywords
This publication has 43 references indexed in Scilit:
- Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's DiseaseAnnals of Neurology, 2024
- Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser ParkinsonismMovement Disorders, 2023
- Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An UpdateMovement Disorders, 2022
- Accelerating Medicines Partnership: Parkinson's Disease. Genetic ResourceMovement Disorders, 2021
- Age at Onset ofLRRK2p.Gly2019SerIs Related to Environmental and Lifestyle FactorsMovement Disorders, 2020
- A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the NetherlandsMovement Disorders, 2020
- Utility and implications of exome sequencing in early‐onset Parkinson's diseaseMovement Disorders, 2018
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson'sAnnals of Neurology, 2016
- Disease Penetrance of Late-Onset ParkinsonismJAMA Neurology, 2014
- Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)Human Mutation, 2008